CM512

Phase 2Biologic

KKeymed Biosciences Co.Ltd

CM512 is one of 108 biologic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseNot yet recruiting

Atopic DermatitisRecruiting

AsthmaRecruiting

Chronic Spontaneous UrticariaNot yet recruiting

Chronic Rhinosinusitis With Nasal PolyposisNot yet recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Not yet recruiting

Atopic DermatitisPhase 2

Recruiting

AsthmaPhase 2

Recruiting

Chronic Spontaneous UrticariaPhase 2

Not yet recruiting

Chronic Rhinosinusitis With Nasal PolyposisPhase 2

Not yet recruiting

Competition

Competitive Landscape

161 competitors in Asthma

#DrugCompanyPhaseTrials

CM512

KKeymed Biosciences Co.Ltd

Phase 2

1 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Ozone

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Atopic Dermatitis

NCT06947980

Q1 2027

Phase 2Not yet recruiting

Chronic Spontaneous Urticaria

NCT07166211

Q3 2027

Phase 2Recruiting

Asthma

NCT07011524

Q4 2027

Phase 2Recruiting

Atopic Dermatitis

NCT07230483

Clinical

Trials by Indication[1]

Atopic Dermatitis3 trials

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

Completed·KKeymed Biosciences Co.Ltd·Phase 1·NCT06553209·110 enrolled

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06947980·200 enrolled

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT07230483·246 enrolled

Chronic Rhinosinusitis With Nasal Polyposis3 trials

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Not yet recruiting·BBeijing Keymed Biosciences Co., Ltd.·Phase 3·NCT07807826·240 enrolled

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis

Completed·KKeymed Biosciences Co.Ltd·Phase 2·NCT06930612·120 enrolled

An Open-Label, Single-Arm, Multicenter, Extension Study to Evaluate the Safety and Efficacy of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis

Not yet recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT07519577·120 enrolled

Asthma1 trial

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT07011524·200 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Not yet recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06980142·204 enrolled

Chronic Spontaneous Urticaria1 trial

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Not yet recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT07166211·48 enrolled

1 more indication

Perennial Allergic Rhinitis1 trial

A Randomized, Double-Blind, Placebo-Parallel Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy

Not yet recruiting·BBeijing Keymed Biosciences Co., Ltd.·Phase 2·NCT07890350·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for CM512. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CM512 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CM512. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Keymed Biosciences Co.Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: KKeymed Biosciences Co.Ltd

CM512

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Atopic Dermatitis3 trials

Chronic Rhinosinusitis With Nasal Polyposis3 trials

Asthma1 trial

Chronic Obstructive Pulmonary Disease1 trial

Chronic Spontaneous Urticaria1 trial

Perennial Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News